NO20083822L - Farmasoytisk antikreftpreparat - Google Patents

Farmasoytisk antikreftpreparat

Info

Publication number
NO20083822L
NO20083822L NO20083822A NO20083822A NO20083822L NO 20083822 L NO20083822 L NO 20083822L NO 20083822 A NO20083822 A NO 20083822A NO 20083822 A NO20083822 A NO 20083822A NO 20083822 L NO20083822 L NO 20083822L
Authority
NO
Norway
Prior art keywords
group
substituted
inhibitor
membered
salt
Prior art date
Application number
NO20083822A
Other languages
English (en)
Inventor
Kosaku Fujiwara
Naomi Shimazaki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of NO20083822L publication Critical patent/NO20083822L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det er beskrevet et farmasøytisk antikreftpreparat for anvendelse ved forebyggelse eller behandling av et karsinom, et sarkom eller hematopoesekreft. Preparatet omfatter en forbindelse representert ved den generelle formel (I) eller et salt derav som en aktiv bestanddel, hvor R er en fenylgruppe substituert med 1-5 substituenter valgt blant et halogenatom, en hydroksygruppe, en Cl-C6-alkylgruppe, en halogen-C1-C6-alkylgruppe, en C1-C6--alkoksygruppe, en Cl-C6-alkyltiogruppe, en amingruppe som kan være substituert, en C3-C10-sykloalkylgruppe som kan være substituert, en alifatisk Cl-C7-acyloksygruppe, en nitrogenert 4-7leddet, mettet, heterosyklisk gruppe, en nitrogenert 5-6-leddet, aromatisk, heterosyklisk gruppe, en nitrogruppe og en cyangruppe; og X er et oksygen- eller svovelatom. Også beskrevet er et farmasøytisk antikreftpreparat som omfatter en inhibitor av epidermal vekstfaktorreseptor (EGFR), en inhibitor av vaskulær endotelvekstfaktorreseptor (VEGFR) eller en Raf-kinaseinhibitor, og en forbindelse representert ved den generelle formel (I) ovenfor, eller et salt derav, som aktive bestanddeler.
NO20083822A 2006-02-09 2008-09-08 Farmasoytisk antikreftpreparat NO20083822L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006031791 2006-02-09
PCT/JP2007/052178 WO2007091622A1 (ja) 2006-02-09 2007-02-08 抗癌医薬組成物

Publications (1)

Publication Number Publication Date
NO20083822L true NO20083822L (no) 2008-11-05

Family

ID=38345216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083822A NO20083822L (no) 2006-02-09 2008-09-08 Farmasoytisk antikreftpreparat

Country Status (15)

Country Link
US (4) US8263631B2 (no)
EP (1) EP1982718A4 (no)
JP (2) JP5133071B2 (no)
KR (1) KR20080101888A (no)
CN (1) CN101415422B (no)
AU (1) AU2007213028C1 (no)
BR (1) BRPI0707671A2 (no)
CA (1) CA2642665C (no)
IL (1) IL193243A0 (no)
NO (1) NO20083822L (no)
NZ (1) NZ570381A (no)
RU (1) RU2419430C2 (no)
TW (1) TW200800181A (no)
WO (1) WO2007091622A1 (no)
ZA (1) ZA200807721B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
TW200838512A (en) * 2007-02-08 2008-10-01 Daiichi Sankyo Co Ltd Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
WO2008126732A1 (ja) * 2007-04-05 2008-10-23 Daiichi Sankyo Company, Limited 縮合二環式ヘテロアリール誘導体
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
EP2196541B1 (en) 2007-09-28 2012-11-07 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
TW201008935A (en) * 2008-07-31 2010-03-01 Daiichi Sankyo Co Ltd Crystalline forms of thiazolidinedione compound and its manufacturing method
US20110160462A1 (en) 2008-07-31 2011-06-30 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
EP2404918B1 (en) 2009-03-05 2016-11-30 Daiichi Sankyo Company, Limited Pyridine derivative as ppary inhibitor
CA2781800A1 (en) 2009-11-26 2011-06-03 Daiichi Sankyo Company, Limited Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
US20140221369A1 (en) * 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
MX371382B (es) * 2013-03-15 2020-01-28 Aerpio Therapeutics Inc Composiciones, formulaciones y metodos para tratar enfermedades oculares.
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP2016062874A (ja) * 2014-09-22 2016-04-25 株式会社ジャパンディスプレイ 画像表示装置及びその製造方法、並びに画像表示装置の検査方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP2019510780A (ja) * 2016-04-04 2019-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌治療用ｌｌｓ化合物
EP3518918A4 (en) * 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
RU2692129C1 (ru) * 2018-03-19 2019-06-21 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования лимфогенного метастазирования у больных при аденокарциноме прямой кишки
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
CN113262306A (zh) * 2021-07-21 2021-08-17 北京大学第三医院（北京大学第三临床医学院） Pparg拮抗剂在肿瘤治疗药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3488099B2 (ja) * 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
PL200859B1 (pl) * 1997-10-08 2009-02-27 Sankyo Co Podstawiony skondensowany związek heterocykliczny, kompozycja farmaceutyczna zawierająca podstawiony skondensowany związek heterocykliczny oraz zastosowanie podstawionego skondensowanego związku heterocyklicznego
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
DE10133394A1 (de) 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
JP2003192592A (ja) * 2001-10-17 2003-07-09 Sankyo Co Ltd 医薬組成物
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
JP2005506366A (ja) * 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
JP2004083558A (ja) 2002-04-01 2004-03-18 Sankyo Co Ltd 抗腫瘍医薬組成物
AU2003220855A1 (en) 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
WO2003106417A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
TW200403055A (en) * 2002-06-25 2004-03-01 Sankyo Co Pharmaceutical composition of a peroxisome proliferator-activated receptor (PPAR) gamma atcivetor and a diuretic
JP2005162727A (ja) * 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2004315404A (ja) * 2003-04-15 2004-11-11 Sankyo Co Ltd ベンゾイミダゾール誘導体を含有する医薬
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
JP2008501651A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー イリノテカン（ｃｐｔ−１１）およびｅｇｆｒ阻害剤を用いた処置
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物

Also Published As

Publication number Publication date
IL193243A0 (en) 2009-02-11
CA2642665C (en) 2013-01-08
AU2007213028B2 (en) 2010-10-28
NZ570381A (en) 2011-02-25
CA2642665A1 (en) 2007-08-16
TW200800181A (en) 2008-01-01
CN101415422B (zh) 2012-11-07
AU2007213028A1 (en) 2007-08-16
US20130183297A1 (en) 2013-07-18
EP1982718A4 (en) 2010-05-12
EP1982718A1 (en) 2008-10-22
JP2012255042A (ja) 2012-12-27
RU2008136188A (ru) 2010-03-20
AU2007213028C1 (en) 2011-05-19
RU2419430C2 (ru) 2011-05-27
US20120258991A1 (en) 2012-10-11
CN101415422A (zh) 2009-04-22
US8263631B2 (en) 2012-09-11
KR20080101888A (ko) 2008-11-21
WO2007091622A1 (ja) 2007-08-16
BRPI0707671A2 (pt) 2011-05-10
JPWO2007091622A1 (ja) 2009-07-02
US20090028868A1 (en) 2009-01-29
JP5133071B2 (ja) 2013-01-30
ZA200807721B (en) 2010-02-24
US20120263716A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
NO20083822L (no) Farmasoytisk antikreftpreparat
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
EA200970569A1 (ru) Применимые в качестве гербицидных соединений пиридопиразиновые производные
ATE517885T1 (de) Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
WO2009155121A3 (en) Inhibitors of pi3 kinase
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
JP2017537882A5 (no)
EA201290260A1 (ru) Бензимидазол-имидазольные производные
JP2017523997A5 (no)
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EA201200826A1 (ru) Инсектицидные соединения, основанные на производных изоксазолина
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
EA200970156A1 (ru) Пиридизиноновые производные
EA201001619A1 (ru) Ингибиторы протеинкиназ
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
EA200802329A1 (ru) Производные триазола ii
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application